Post Profile






Encouraging Results For Ribociclib In Advanced Breast Cancer

Ribociclib is one of several CDK inhibitors being tried in breast cancer and other malignancies. The problem is not that these new drugs don’t work, but their costs, and how to test their use in combinations, against multiple tumor types, in clinical trials that don’t cost a fortune.
read more

share

Related Posts


MD Anderson-led study finds ribociclib improves progression-free survival for women with metastatic breast cancer

Health : EurekAlert: Health

(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatic...

Ribociclib improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast can...

Potential new drug effective in breast cancer and melanoma resistant to targeted therapies

Academics / General Science : Science Codex

BOSTON — LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination ...

Potential new drug effective in breast cancer, melanoma resistant to targeted therapies

Academics / General Science : ScienceDaily: Science Society

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 has showen promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies. Based on the...

Preclinical results show potential new drug effective against drug-resistant melanoma and drug-resistant breast cancer

Health : Medical News Today

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with othe...

Comments


Copyright © 2016 Regator, LLC